Earnings Releases·Nov 9, 2026, 8:01 AM ET

Orthofix Medical Inc. — Third Quarter 2026 Earnings Summary

Reported net sales reached $207.9 million, up 1.1% year-over-year, while the company narrowed its net loss to $(6.1) million compared to $(22.8) million in the prior year period.
Full-year 2026 guidance was revised downward, with pro forma net sales lowered to $825–$830 million and non-GAAP adjusted EBITDA reduced to $86–$88 million.
Segment performance showed growth in Global Limb Reconstruction (+8%) and Therapeutic Solutions (+4%), which offset a 1.1% decline in Spinal Implants, Biologics, and Enabling Technologies.
Management is accelerating execution improvements in U.S. Spine, including instrument set availability and asset productivity, to address weaker spine performance and drive future profitability.